Visceral leishmaniasis (LEASH-ma-NIGH-a-sis) is a parasitic disease that kills about 60,000 people annually. The current issue of ACS Chemical Biology reported a development of a new candidate or potential vaccine for leishmaniasis disease.
Peter H. Seeberger, Ph.D., of the Laboratory for Organic Chemistry at the Swiss Federal Institute of Technology (ETH) in
Zurich headed the research group. It also included researchers from the Swiss Tropical Institute in Basel and Pevion Inc., a biotech company focusing on virosomal delivery systems. The group reported their findings in ACS Chemical Biology, one of 34 peer-reviewed journals published by the American Chemical Society, the world's largest scientific society.
No effective vaccine for visceral or internal form of leishmaniasis disease exists despite major research thrust by the World Health Organization (WHO).
Seeberger’s research team reported the development of a carbohydrate-based vaccine, the first and only carbohydrate vaccine against this disease.
Read more at Science Daily.
Comment Preview